Enterovirus A71 vaccines currently include three inactivated, whole-virus vaccines licensed in China, while virus-like particles and recombinant VP1 vaccines remain under development.
This review highlights the current landscape of EV-A71 vaccines, noting three licensed inactivated vaccines and ongoing development of novel vaccine types.
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
Li et al. (Sat,) conducted a review in Enterovirus A71 infection. Enterovirus A71 vaccines was evaluated. Enterovirus A71 vaccines currently include three inactivated, whole-virus vaccines licensed in China, while virus-like particles and recombinant VP1 vaccines remain under development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: